will AI replace dermatologists?

Sixteen of eighteen tasks in your role have zero AI penetration, according to O*NET task data. That's not a rounding error. Performing an incisional biopsy to diagnose melanoma, examining a mole under dermoscopy, deciding whether that lesion on a 58-year-old's back is a seborrheic keratosis or something that needs to come off — those decisions sit with you. No AI system can hold a scalpel or take the legal and clinical responsibility for getting it wrong.

The physical examination is irreplaceable. You're reading texture, colour gradation, border irregularity, and patient affect all at once. You're noticing that the patient mentioned sun exposure casually while you're looking at a suspicious patch on their shoulder. That context loop, where the conversation shapes what you're seeing and what you're seeing shapes the next question, can't be replicated by a tool that looks at a photograph. Counselling patients on skin cancer awareness, explaining why they need annual screenings, getting a 40-year-old who tans aggressively to actually change behaviour — that's clinical communication, and it requires a person in the room.

Prescribing the right combination of spironolactone and a topical retinoid for a woman with hormonal acne, then adjusting three months later based on how her skin responded and what side effects she's tolerating, is clinical judgment built on years of training. It also carries liability. AI can surface drug interactions from a database. It can't own the decision. You can.

AI image recognition for skin conditions sounds impressive in press releases. In practice, it has a serious accuracy problem at the edges of the distribution, which is exactly where the stakes are highest. A tool trained on dermoscopy images from research databases may perform well on classic presentations of melanoma. It performs much worse on darker skin tones, on rare variants, or on lesions that don't fit a clean pattern. A 2022 study in the Journal of the American Academy of Dermatology found that several AI diagnostic tools showed significant drops in accuracy when tested on images from patients with Fitzpatrick skin types IV through VI.

Liability is the other wall AI keeps hitting. If an AI system flags a lesion as benign and it turns out to be stage II melanoma, who is responsible? The software vendor? The hospital? You? Right now, that ambiguity means AI diagnostic suggestions in dermatology are treated as a second opinion at best, not a clinical decision. Regulators haven't resolved this, and that alone keeps the human in the loop. And AI systems can't perform procedures. They can't do excisions, chemical peels, patch testing for contact dermatitis, or cryotherapy. The entire procedural side of your work is off the table for AI entirely.

The two tasks where AI actually helps are literature review and patient record documentation. These are real time-savers, even if they're not the heart of the job. Tools like Consensus and Elicit can scan recent dermatology literature and pull relevant findings faster than a manual PubMed search. If you're trying to stay current on new biologics for atopic dermatitis or check whether there's emerging data on a particular immunosuppressant regimen, these tools cut research time meaningfully.

For documentation, ambient AI tools like DAX Copilot and Nabla can listen to a patient encounter and generate a draft clinical note, including the history of presenting complaint, examination findings, and plan. You review and edit it rather than dictating from scratch. In a specialty where a busy clinic day might run 25 to 30 patients, that time adds up. Some dermatology-specific EHR add-ons, including those integrated into Modernizing Medicine's EMA system, can pre-populate structured fields based on your spoken documentation.

There are also AI-assisted dermoscopy tools worth knowing, like DermEngine and SkinVision, which are FDA-cleared to flag potentially suspicious lesions. These are used as screening aids, particularly in primary care settings where a dermatologist isn't present, rather than as diagnostic replacements. In your hands, they're a triage layer, not a substitute for your clinical assessment. The marketing around these tools overstates what they do. The documentation ones actually save time.

The biggest shift is at the edges of the day, not in the exam room. Pre-clinic prep, where you'd skim literature or review flagged studies, is faster now. The research tools covered above mean you're spending less time hunting and more time reading. That's a genuine improvement.

Documentation is the other change. If you're using an ambient tool, the note-writing that used to happen after hours, or in the 90 seconds between patients, is now a review task rather than a creation task. You're reading and signing off rather than dictating. That's not nothing. In a full clinic day, it can return 45 minutes to an hour. What you spend more time on is what was always the hard part: the complex cases, the patients who need more counselling, the tricky differential between two conditions that look similar on the surface.

The exam room itself hasn't changed at all. You're still examining skin. You're still asking about family history, medications, and sun exposure. You're still making the call. No part of the clinical encounter has been handed to a machine, and nothing in current AI development suggests that's about to change in the near term.

The BLS projects 6.4% growth for physicians and surgeons, including dermatologists, through 2034. With only about 10,900 dermatologists employed nationally and 400 openings per year, this is already a supply-constrained specialty. Wait times for dermatology appointments in the US average 36 days according to Merritt Hawkins survey data, and in some regions run past 70 days. That's not a market where automation is eating jobs. It's a market where demand outpaces supply and has for years.

AI tools in this space, particularly teledermatology platforms and AI triage for primary care, may actually increase referral volume to dermatologists rather than reduce it. If a primary care physician uses an AI screening tool that flags more suspicious lesions, those patients need to see someone. That someone is you. The net effect of AI deployment in adjacent settings is likely more patients in your queue, not fewer.

Geographic distribution matters here too. Dermatologists are concentrated in urban and suburban markets. Rural access is a real problem, and AI-assisted teledermatology is being deployed to fill that gap. But that's not replacing dermatologists in those markets because there weren't enough dermatologists there to begin with. It's extending reach, and the specialist on the other end of the telehealth consultation is still a trained physician.

The AI exposure score for dermatologists sits at effectively zero right now, and that's unlikely to change dramatically in the next five years. For the score to rise significantly, AI would need to handle clinical diagnosis with enough accuracy and legal standing to be trusted without a physician reviewing every case. That requires regulatory frameworks that don't exist yet, liability structures that haven't been resolved, and accuracy rates on diverse populations that current tools don't achieve. None of those are five-year problems.

The ten-year picture is more uncertain. If AI image analysis closes the accuracy gap on diverse skin tones, and if FDA clearance expands to cover more diagnostic applications, you might see AI take on more of the screening function in lower-acuity settings. But the procedural work, the surgical interventions, the complex multi-system cases, the patient relationships built over years of managing a chronic condition like psoriasis, those stay with you. The most realistic long-term scenario isn't fewer dermatologists. It's dermatologists doing more of the complex work while AI handles the first-pass triage in primary care.

Double down on procedures. Excisions, Mohs surgery, laser treatments, chemical peels, intralesional injections — the procedural side of dermatology is where AI has zero footprint and is likely to stay that way. If you're earlier in your career, building surgical volume and pursuing fellowship training in procedural or surgical dermatology is the most durable career move you can make. Procedures are also where reimbursement is strongest, which matters for private practice economics.

Consultative and complex case work is the other area worth developing deliberately. Dermatologists who handle difficult diagnostics, rare conditions, or multi-system inflammatory diseases are doing work that requires integrating clinical history, lab data, biopsy results, and treatment response over time. That's not pattern matching on a photograph. The more you're the person other clinicians call for a complicated case, the less substitutable you are.

On the technology side, it's worth getting comfortable with the documentation tools covered earlier, not because they're exciting but because they buy back time. That time is better spent on patient relationships and clinical complexity than on note writing. If your practice or hospital system is evaluating AI triage tools for teledermatology, get involved in that evaluation. Understanding what these tools can and can't do makes you better at using them appropriately and better at catching when they're wrong. The dermatologists who'll feel most secure in ten years aren't the ones who avoided the technology. They're the ones who understood it well enough to stay in charge of it.